Maravai LifeSciences Stock (NASDAQ: MRVI)

Maravai LifeSciences (NASDAQ:MRVI) Stock, Quote.Headers.trade-ideas

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

wall street future ai

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

AMAT

AMCR

COHR

SPDR Dow Jones Industrial Average ETF Trust

Market Vectors ETF Trust Market Vectors Gold Miners

GLOB

MRVI

RGEN

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street edged slightly higher on Friday, with major equity indices showing modest gains at midday in New York.

Wall Street Gains Ground As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What&#39;s Driving Markets Friday?

Movers

News

Intraday Update

Markets

Trading Ideas

ASTI

ASTS

AWIN

BNAI

BNZI

CAVA

CHWY

CNEY

CRKN

FFIE

GENE

GYRE

HLTH

IKNA

IMVT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

NEON

ONFO

OOMA

POAI

RSLS

SCPX

SMLR

SOBR

SOPH

SRDX

STSS

SYTA

TANH

TITN

TOST

VERU

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Penny Stocks

Small Cap

ABSI

BILI

LYEL

MRNA

NRIX

RVNC

TSHA

TSLA

XPEV

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.

Shares of  BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session.

BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Vice President <a href="https://www.benzinga.com/news/24/09/40973752/kamala-harris-reportedly-set-to-unveil-new-economic-policies-in-pittsburgh-this-week-its-about-showi">Kamala Harris </a>was ahead of her Republican rival Donald Trump, going by the results of two separate polls published over the weekend.
The Matchups: Harris was ahead of Trump by five points in a one-on-one contest, with the tally at 49%-44%, a national NBC News <a href="https://www.nbcnews.com/politics/2024-election/poll-newly-popular-harris-challenging-trump-change-rcna171308">poll</a> conducted Sept. 13-17 with 1,000 registered voters showed. The survey&#8217;s margin of error was plus or minus 3.1 percentage points. This marked a shift from the sentiment that prevailed when NBC News did its July polls. When President Joe Biden was still in the race, Trump was ahead by two points.
The results of the Harris vs. Trump matchup showed Black voters siding with the former by an 85%-7% tally. Harris received majority support among voters, aged 18-34 years (57%-34%) and voters with college degrees 59%-38%). Among independents, the vice president received a singularity of votes (43%-35%).
Trump&#8217;s support base is among men (52%-40%), white voters (52%-43%) and white voters without college degrees (61%-33%).
In a welcome development for Harris and the Democrats, support for the party reached its highest point in NBC News polling since mid-2023. At the same time, the share of voters saying they were undecided or wanted another choice dipped to its lowest point since that time.
A CBS/YouGov <a href="https://www.cbsnews.com/news/trump-harris-poll-debate-economy-09-22-2024/">poll </a>conducted between Sept. 18-20&nbsp;showed Harris leading yet again, with the margin at 52%-48% among likely voters. About 3,129 registered voters nationwide&nbsp;were contacted for the purpose, with the margin of sampling error at plus, or minus 2.2 points.
In the CBS/YouGov poll, Harris was ahead in the battleground states with a slightly smaller margin. She received 51% support and Trump 49%.
Harris scores better among the subset who think the economy is good and/or their personal finances are good. Eighty-eight percent of those who said the economy is good backed her and 64% of those who said their personal finances are good supported her.
Republican pollster Bill McInturff of Public Opinion Strategies, who did NBC News poll along with Democratic pollster said Jeff Horwitt of Hart Research Associates said Trump&#8217;s eroding support was due to some Republicans, who are not his die-hard supporters, deserting him. But this could change, he said.
We have seen this movie before. They can get squishy on Trump, and then in the end they come back and they vote the way they're going to vote on a Republican-versus-Democrat preference for Congress,&#8221; said McInturff.
CBS/YouGov poll found that people who prioritize the personal qualities of a candidate are voting&nbsp;for Harris (66%-33%) and those who say policies are very important are evenly split between them.&nbsp;
Multi-Candidate Fray: When the ballot included Robert F. Kennedy Jr., Green Party&#8217;s Jill Stein and Libertarian Chase Oliver, Harris had a bigger lead, 47% of the registered voters favored her and 41% Trump, while the other candidates managed 2% or less each, according to NBC News poll.
See Also: <a href="https://www.benzinga.com/24/09/40971977/elon-musk-says-biden-belied-his-2020-expectations-and-turned-out-to-be-a-radical-leftist-puppet-why">Elon Musk Says Biden Belied His 2020 Expectations And Turned Out To Be A &#8216;Radical Leftist Puppet&#8217;: Why Billionaire Is Supporting Trump This Time Around</a>
Harris Surges, Trump Sedate: NBC News poll showed that Harris&#8217; popularity has improved notably since July when she had a net negative rating of 18, courtesy of 32% of voters holding positive opinions about her and 50% seeing her in a negative light. In the September poll, her favorability improved to a net positive 3 points, with 48% and 45%, respectively, rating her positively and negatively.
No major-party presidential candidate in the 35-year history of the NBC News poll has seen this kind of jump in popularity in an election, the pollster said.
Trump&#8217;s net rating was essentially unchanged from July at a net negative 13 points.
Economy &#8211; The Achilles&#8217; Heel: Harris has her fair share of pitfalls. In the CBS News/YouGov survey, among likely voters who mentioned the economy is a major concern, she trailed by a 47%-53% margin. That said, it has been an improvement from the tally in August when she trailed by a 43%-56% margin. 
The proportion of the registered voters who said the economy is good improved from 35% in August to 39% currently and the proportion who said the economy is bad fell from 62% to 59%.
The NBC News poll found that two-thirds of voters said their family income is falling behind the cost of living, and voters mentioned the cost of living as their top concern, handing Trump the advantage on the economy and inflation. The former president&#8217;s advantage, however, reduced relative to what it was when he was pitched against Biden in July.
 The Consumer price inflation has been on a sustainable downward trajectory so much that it allowed the<a href="https://www.benzinga.com/markets/equities/24/09/40965372/fed-delivers-large-interest-rate-cut-in-bid-to-sustain-labor-market-stocks-gold-set-new-record-h"> Federal Reserve to drop the Fed funds rate by 50 basis points </a>last week. With interest rates receding from their highs, consumers, who fuel much of the economic growth, can now heave a sigh of relief.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Wikimedia Commons

Politics

Topics

Media

General

Trump Vs. Harris: Vice President Leads In 2 More New Polls But Pollster Says Undecided Republicans Can Come Back Home To Bolster Ex-President

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release earnings results for its third quarter, after the closing <a href="https://www.benzinga.com/quote/KBH/earnings">bell on Tuesday, Sept. 24</a>.
Analysts expect the Los Angeles, California-based company to report quarterly earnings at $2.06 per share, up from $1.80 per share in the year-ago period. KB Home is projected to post quarterly revenue of $1.73 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 18, the company's board of directors declared a quarterly cash dividend of 25 cents per share on the company&#8217;s common stock.
KB Home shares fell 2.7% to close at $87.23 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/596530e4988ca80001209fc0/rafe-jadrosich">B of A Securities analyst Rafe Jadrosich</a> maintained a Neutral rating and raised the price target from $75 to $90 on Sept. 19. This analyst has an accuracy rate of 72%.</li>
<li>Wedbush analyst Jay McCanless reiterated a Neutral rating with a price target of $67 on Sept. 12. This analyst has an accuracy rate of 84%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/63b6dd8f392e5e0001e663df/sam-reid">Wells Fargo analyst Sam Reid</a> maintained an Equal-Weight rating and raised the price target from $70 to $80 on Sept. 9. This analyst has an accuracy rate of 85%.</li>
<li>RBC Capital analyst Mike Dahl downgraded the stock from Sector Perform to Underperform with a price target of $70 on Sept. 5. This analyst has an accuracy rate of 74%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/594d093f988ca8000150db5a/susan-maklari">Goldman Sachs analyst Susan Maklari</a> maintained a Neutral rating and increased the price target from $72 to $82 on Sept. 3. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying KBH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23033739/image-170-1024x510.png" alt="" class="wp-image-560499" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23033739/image-170-1024x510.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23033739/image-170-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23033739/image-170-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23033739/image-170.png 1348w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

KB Home Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.semtech.com%2F&amp;esheet=54125475&amp;newsitemid=20240923889065&amp;lan=en-US&amp;anchor=Semtech+Corporation&amp;index=1&amp;md5=c57e2a9ac357ffdffffa11ede356e87f">Semtech Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>), a high-performance semiconductor, IoT systems, and cloud connectivity service provider, today announced sampling of GN2255S, its next generation Tri-Edge&#x2122; 50 Gbps clock and data recovery (CDR) with integrated DML driver for SFP56 50G PAM4 bidirectional (BiDi) and CWDM6 optical modules. As part of the industry's only analog solutions for 50 Gbps fronthaul, the new CDR can lead to simpler, potentially more power-efficient designs. Its real-time signal processing delivers ultra-low latency crucial for 5G Advanced time-critical services, such as required in public safety, industrial control, smart grid management, and more.
&nbsp;
According to the latest <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ericsson.com%2Fen%2Freports-and-papers%2Fmobility-report%2Fmobility-visualizer%3Ff%3D1%26ft%3D1%26r%3D2%2C3%2C4%2C5%2C6%2C7%2C8%2C9%26t%3D8%26s%3D1%2C2%2C3%26u%3D1%26y%3D2020%2C2026%26c%3D1&amp;esheet=54125475&amp;newsitemid=20240923889065&amp;lan=en-US&amp;anchor=Ericsson+Mobility+Report&amp;index=2&amp;md5=6f1dfa0cec9395190734d0790d78e533">Ericsson Mobility Report</a>, 5G subscriptions will more than double from 2024 to 2029, with mobile data traffic forecast to exceed 230 exabytes monthly by 2029. Exponential data demands, along with use cases like generative AI, machine learning (ML), and augmented reality (AR), will drive infrastructure upgrades. With its faster data transfer and improved connectivity, integration of 5G advanced technology will further boost network performance, intelligence, and sustainability.
"As a Mobile Optical Pluggable Alliance (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmopa-alliance.org%2F&amp;esheet=54125475&amp;newsitemid=20240923889065&amp;lan=en-US&amp;anchor=MOPA&amp;index=3&amp;md5=9b066949d6ddee948fafcbbf6a32132f">MOPA</a>) founding member, Semtech works closely with the world's telecom leaders and mobile operators to develop the right optical solutions that solve industry challenges," said Raza Khan, product marketing director for Semtech's Signal Integrity Products Group and chief marketing officer of MOPA. "Our Tri-Edge solutions for bidirectional and CWDM optical pluggables are a direct result of these collaborations. Enabling the next round of infrastructure upgrades over single fiber will give carriers greater cost-effectiveness, flexibility and scalability to advance global mobile networks."
"Optical pluggable innovations like Semtech's move the industry towards the high performance and latency needed for global mobile networks to become the digital backbone of society and industry 4.0," said Stefan Dahlfort, chairman and president of the board of MOPA.
Semtech at ECOC 2024
Semtech's demos in booth E37, MR21, MR22 will showcase solutions for datacenter, wireless, and PON. Meetings are by appointment only.

SMTC

Semtech Showcases 50G Optical Module Innovations at ECOC 2024, Targets 5G and 6G Networks

Stifel foresees a significant market downturn by the end of 2024. Chief equity strategist Barry Bannister <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40701071/market-bull-warns-of-up-to-10-september-pullback-urges-caution-but-stresses-be-read">warned the S&amp;P 500 could fall by 12% in the fourth quarter</a>.
What Happened: Bannister highlighted various concerns, including high valuations and speculative investor behavior. &#8220;Our instruments tell us to expect an S&amp;P 500 correction to the very low 5,000s by 4Q24,&#8221; he stated, <a href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-strategist-warns-correction-soon-tech-bubble-risk-2024-9">reported</a> Business Insider.
He noted that current stock market valuations are nearing a &#8220;near three-generation high&#8221; with the S&amp;P 500&#8217;s price-to-earnings multiple around 24x. Additionally, the outperformance of large-cap growth stocks relative to value stocks is reminiscent of peaks seen in February 2000 and August 2020, which preceded bear markets.
Bannister also pointed out that rising labor supply from increased immigration has bolstered economic growth, but overall labor demand is waning. &#8220;Fading labor demand is now symbolic of recession risk,&#8221; he said, mentioning that the non-farm payroll 6-month diffusion index has dipped below a &#8220;recession trigger level.&#8221;
He further explained that the typical &#8220;pre-election juice&#8221; for the economy might diminish towards year-end, impacting stock performance. Lastly, Bannister warned of a potential bubble in technology stocks, comparing it to the dot-com bubble of the 1990s.
See Also: <a href="https://www.benzinga.com/news/24/09/40969895/support-for-taylor-swifts-get-out-the-vote-efforts-have-dropped-15-points-since-february-amid-super?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Support For Taylor Swift&#8217;s Get-Out-The-Vote Efforts Have Dropped 15 Points Since February Amid Super Bowl Conspiracy Theory</a>
Why It Matters: The warning from Stifel comes on the heels of several significant market events. 
Additionally, in early September, equity strategist Tom Lee warned of a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40701071/market-bull-warns-of-up-to-10-september-pullback-urges-caution-but-stresses-be-read">potential 7%-10% market pullback</a>, attributing this to historical trends showing September as the weakest month for stocks. Lee urged caution but also advised investors to be ready to &#8220;buy that dip.&#8221; 
More recently, the Federal Reserve&#8217;s decision to cut interest rates by 0.5% <a href="https://www.benzinga.com/news/24/09/40969943/fed-rate-cut-fuels-market-rally-amidst-valuation-fears">triggered a market rally</a>, despite concerns over inflated valuations. This move led to a significant surge in U.S. stocks and commodities, while reducing bond market volatility.
The rate cut also influenced investor behavior, with a shift away from money market funds and into <a href="https://www.benzinga.com/economics/24/09/40965570/fed-rate-cut-may-drive-investors-away-from-money-markets-says-portfolio-manager">longer-duration bonds</a>, as noted by fixed-income portfolio manager Timothy Ng.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40951546/big-short-fame-investor-drops-previous-prediction-of-trump-victory-the-market-is-going-straight-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Big Short&#8217; Fame Investor Drops Previous Prediction Of Trump Victory: &#8216;The Market Is Going Straight Down&#8217; If Kamala Harris Wins White House And Democrats Sweep Congress</a></li>
</ul>
Image via Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Global

Stifel Warns Of 12% Market Drop By End Of 2024 As S&P 500 Faces High Valuations And Speculative Risks

Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://www.benzinga.com/news/24/09/40680904/7-products-apple-will-likely-discontinue-next-week-after-iphone-16-launch">has discontinued</a>&nbsp;the iPhone 15 Pro, iPhone&nbsp;15 Pro Max, and iPhone 13 models, along with other products,&nbsp;as part of its annual&nbsp;product streamlining.
What Happened: Apple has stopped production of several products, but these models can still be found in stock at online and third-party retail stores for a limited time.
Apple&#8217;s annual product discontinuation is a routine practice, making way for newer items. This year,&nbsp;the oldest iPhone still in&nbsp;production, the iPhone 13, was also dropped, <a href="https://appleinsider.com/articles/24/09/22/in-with-the-new-out-with-the-old-apple-discontinues-the-iphone-15-pro-iphone-13">reported</a> AppleInsider.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/40911877/jeff-bezos-had-a-habit-of-keeping-an-empty-chair-for-the-most-important-person-in-the-room-at-compan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jeff Bezos Had A Habit Of Keeping An Empty Chair For The Most Important Person In The Room At Company Meetings: This Strategy Helped The Amazon Founder Build The E-Commerce Giant We Know Today</a>
The current iPhone lineup now includes the iPhone 14 and iPhone 14 Plus, iPhone 15 and&nbsp;iPhone 15 Plus, the four <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">new&nbsp;iPhone 16 models</a>, and the&nbsp;third-generation iPhone SE from 2022.
Other discontinued products include the AirPods Max, replaced by nearly identical models with new colors and a USB-C port.
The regular AirPods&nbsp;2 and AirPods 3 have&nbsp;also been replaced with two&nbsp;new models of AirPods 4.&nbsp;After the introduction of&nbsp;the Apple Watch Series 10,&nbsp;the Apple Watch Series 9 was also discontinued.
Apple&nbsp;also dropped its line of FineWoven iPhone cases due to negative customer feedback, the report noted.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The discontinuation of these models comes amid mixed reports about the demand for the new iPhone 16.&nbsp;T-Mobile US Inc. CEO Mike Sievert&nbsp;said that the iPhone 16 is selling at a <a href="https://www.benzinga.com/markets/equities/24/09/40932937/apple-iphone-16-selling-at-a-greater-rate-than-last-year-says-t-mobile-ceo-amid-reports-of-lower">greater rate than last year&#8217;s model</a>.
However,&nbsp;<a href="https://www.benzinga.com/tech/24/09/40930388/apple-iphone-16-pre-orders-show-possible-low-demand-one-sign-could-point-to-company-breaking-this-em">analysts predicted weak demand</a>&nbsp;for the iPhone 16 due to a lack of reasons for existing iPhone owners to upgrade to the latest model.
JPMorgan analyst Samik Chatterjee&nbsp;has noted that the <a href="https://www.benzinga.com/news/24/09/40882969/iphone-16-pro-demand-lags-longer-wait-times-globally-china-shows-smaller-gap-analyst">lead times of the iPhone 16 series</a> across critical markets, including the U.S., China, Germany, and the U.K., indicate in-line demand for the iPhone 15 series during the first week.
Previously, it was reported that the iPhone 16 series launch also <a href="https://www.benzinga.com/news/24/09/40785959/iphone-16-fails-to-sway-some-chinese-buyers-im-going-to-buy-huaweis-tri-fold-phone-missing-ai-featur">failed to impress some Chinese buyers</a> due to its lack of AI features.
Photo courtesy: Apple
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40968348/whats-next-the-future-with-bill-gates-microsoft-co-founder-unveils-behind-the-scenes-of-his?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;What&#8217;s Next? The Future With Bill Gates&#8217;: Microsoft Co-Founder Unveils Behind The Scenes Of His New Netflix Series</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

AAPL

iPhone 15 Pro Models and iPhone 13 Discontinued By Apple: Here's Why

Biohaven Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia.
&nbsp;
 Biohaven will hold a live conference call and webcast Monday, September 23, 2024, at&nbsp;8:30 a.m. Eastern Time. The live event may be accessed via the Investor Relations portion of Biohaven's website at&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260062-1&amp;h=3860713886&amp;u=https%3A%2F%2Fir.biohaven.com%2Fevents-presentations%2Fevents&amp;a=https%3A%2F%2Fir.biohaven.com%2Fevents-presentations%2Fevents">https://ir.biohaven.com/events-presentations/events</a>.&nbsp;To participate in the live conference call via telephone, please register&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260062-1&amp;h=3868013617&amp;u=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBI8f49496d1a3a4b51a653f73b99957cfb&amp;a=here">here</a>. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.

BHVN

Reported Friday, Biohaven to Announce Topline Data for Troriluzole Spinocerebellar Ataxia Study, Conference Call Set for Sept 23

China&#8217;s central bank has taken significant steps to support the economy by reducing a key short-term interest rate and <a href="https://www.benzinga.com/markets/asia/24/09/40951221/bank-of-japan-leaves-interest-rate-at-0-25-diverging-from-feds-50-basis-point-cut">injecting substantial liquidity into the financial system</a>.
What Happened: The People's Bank of China cut the 14-day reverse repurchase interest rate by 10 basis points to 1.85% and injected 74.5 billion yuan ($10.6 billion) of liquidity via this policy tool, according to its website.
Additionally, the central bank injected 160.1 billion yuan (&nbsp;$10.6 billion) through 7-day reverse repo agreements, maintaining the interest rate at 1.7%, the bank stated on Monday.
Last week, the PBOC unexpectedly kept its benchmark lending rates steady, despite rising expectations for easing following the U.S. Federal Reserve&#8217;s rate cut.
See Also: <a href="https://www.benzinga.com/government/24/09/40923879/chinas-ymtc-makes-strides-in-chip-production-substitutes-asml-lam-research-tech-as-us-sanctions-bite?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">China&#8217;s YMTC Makes Strides in Chip Production; Substitutes ASML, Lam Research Tech As US Sanctions Bite: Report</a>
Why It Matters: The recent actions by the People's Bank of China come amid a global trend of monetary policy adjustments. On Thursday, the Bank of Japan opted to maintain its <a href="https://www.benzinga.com/markets/asia/24/09/40951221/bank-of-japan-leaves-interest-rate-at-0-25-diverging-from-feds-50-basis-point-cut">benchmark interest rate at 0.25%</a>, diverging from the U.S. Federal Reserve&#8217;s 50 basis point cut. 
On Friday, a portfolio manager noted that the Federal Reserve's rate cut could drive <a href="https://www.benzinga.com/economics/24/09/40965570/fed-rate-cut-may-drive-investors-away-from-money-markets-says-portfolio-manager">investors away from money market</a> funds and into longer duration bonds.
Additionally, Federal Reserve Governor Michelle W. Bowman defended her decision to <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40965082/feds-historic-dissenter-bowman-says-smaller-interest-rate-cut-was-justified-we-have-no">support a smaller 25-basis-point rate cut</a>, citing ongoing inflation concerns. This marked a historic moment as it was the first time since 2005 that a Fed governor openly disagreed with a rate decision.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40973148/tsmc-and-samsung-explore-100b-chip-megafactories-in-uae-amid-ai-boom-and-global-expansion-plans-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">TSMC And Samsung Explore $100B Chip Megafactories In UAE Amid AI Boom And Global Expansion Plans: Report</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Asia

China's Central Bank Follows Fed's Dovish Move, Cuts Key Short-Term Rates, Injects Over $10B To Boost Economy

CLVT

Clarivate Announced A Strategic Partnership With Relatable Healthcare, A Technology Company Delivering Product Relationship Management (PRM) Software To Leading Medtech Companies To Drive Revenue And Workflow Efficiency

NDAQ

Nasdaq Announced It Has Expanded Its Digital Bank Financial Technology Presence In Latin America, Having Agreed To Provide Its AxiomSL Regulatory Reporting Solution To Nubank

Empire Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EP#NYSE">EP</a>) ("Empire" or the "Company"), an oil and gas company with current producing assets in New Mexico, North Dakota, Montana, Texas, and Louisiana, announced today that its Board of Directors has fixed the close of business on September 30, 2024 as the record date (the "Record Date") for a subscription rights offering ("Rights Offering") pursuant to which it intends to raise gross proceeds of up to approximately $10 million. The Company will distribute at no charge to holders of its common stock, par value $0.001 per share ("Common Stock"), as of the close of business on the Record Date one subscription right for each share of Common Stock held. Each subscription right will entitle the holder to purchase 0.063 shares of Common Stock at a subscription price of $5.05 per share. If fully subscribed, this would result in the issuance of an aggregate of approximately 1.98 million shares of Common Stock. The subscription rights are non-transferable, and will not be listed for trading on any stock exchange or market. In addition, holders of subscription rights who fully exercise their subscription rights will be entitled to over-subscribe for additional shares of Common Stock, subject to proration.
The Rights Offering is expected to expire at 5:00 p.m., Eastern Time, on October 16, 2024 ("Expiration Date"), subject to extension or earlier termination.

Offerings

Reported Friday, Empire Petroleum Announces $10M Rights Offering, Record Date Set for September 30

Mobile-health Network Solutions (NASDAQ:<a href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) ("MaNaDr" or "the Company"), a leading Asia-Pacific telehealth provider, today announced that it received a notice dated September 18, 2024, from the Listings Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share of its Class A ordinary shares ("Class A Ordinary Shares") was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). The Nasdaq notification letter does not result in the immediate delisting of the Company's Class A Ordinary Shares, and the shares will continue to trade uninterrupted under the symbol "MNDR." &nbsp;
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of one hundred eighty (180) calendar days, or until March 17, 2025 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's Class A Ordinary Shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance, and the matter will be closed.
In the event the Company does not regain compliance by March 17, 2025, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten (10) business days prior to March 17, 2025, or the expiration of the second compliance period if granted.

Government

Regulations

MNDR

Reported Friday, MaNaDr Receives Nasdaq Notice for Minimum Bid Price Rule Violation, Has Until March 2025 to Comply

Saba Capital Income &amp; Opportunities Fund II (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SABA#NYSE">SABA</a>) (the "Fund"), a registered closed-end management investment company listed on the New York Stock Exchange, today announced that its Board of Trustees has renewed its share repurchase authorization for the Fund to repurchase up to 10% of its total common shares for the fiscal year ending October 31, 2025.
The share repurchase program is intended to increase the Fund's net asset value ("NAV") to the benefit of all shareholders and help create further value for shareholders by reducing the Fund's discount to NAV.
The Fund may repurchase shares through open market transactions, at the discretion of the Fund's investment adviser. In exercising its discretion consistent with its portfolio management responsibilities, the investment adviser will take into account various factors, including, but not limited to, timing, the quantity of repurchases, the level of the discount, the Fund's performance, portfolio holdings, dividend history and objectives, market conditions, cash on hand, the availability of other attractive investments, and whether the sale of certain portfolio securities would be undesirable because of liquidity concerns or because the sale might subject the Fund to adverse tax consequences. Any repurchases would be made on a national securities exchange at the prevailing market price, subject to exchange requirements, federal securities laws and rules that restrict repurchases.
There is no assurance that the market price of the Fund's shares, either absolutely or relative to net asset value, will increase as a result of any share repurchases, or that the program will enhance shareholder value. Investment return and principal value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. Investors should consider the investment objective, risks and expenses carefully. You can obtain the Fund's most recent periodic reports and filings by visiting <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2Fedgar%2Fbrowse%2F%3FCIK%3D828803%26owner%3Dexclude&amp;esheet=54125321&amp;newsitemid=20240920050661&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sec.gov%2Fedgar%2Fbrowse%2F%3FCIK%3D828803%26amp%3Bowner%3Dexclude&amp;index=1&amp;md5=6ea55a096c339655a4603de599e135e0">https://www.sec.gov/edgar/browse/?CIK=828803&amp;owner=exclude</a>.

Buybacks

SABA

Reported Friday, Saba Capital Fund II Announces 10% Share Buyback Plan, Targets NAV Improvement

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today successfully launched its 53rd Electron mission and deployed five satellites to Low Earth Orbit for French Internet-of-Things (IoT) company Kinéis.
&nbsp;
&nbsp;
Rocket Lab's Electron takes to the skies for its 53rd launch out of Mahia, NZ, for return French Internet-of-Things customer, Kinéis. Photo Credit: Rocket Lab
The ‘Kinéis Killed the RadIOT Star' lifted off from Rocket Lab Launch Complex 1 in Mahia, New Zealand, at 11:01 a.m. on 21 September NZST (23:01, 20 September UTC), successfully deploying five satellites to a 643 km orbit. The mission was the second of five dedicated Electron launches for Kinéis, a company backed by private and public investors including the French government's space agency CNES (Centre National d'Études Spatiales) and CLS (Collecte Localisation Satellites), an international space-based solutions provider, to improve global IoT connectivity. The Kinéis constellation is designed to make it possible to connect and locate any connected object anywhere in the world, enabling data transmission to users in near-real time, at low bit rates and with very low energy consumption. By enabling internet connection to the Earth's most remote locations, Kinéis constellation can support forest fire detection, water resource management, infrastructure and energy network monitoring, transport and logistics tracking, and much more.
Rocket Lab founder and CEO Sir Peter Beck said: "Today's successful launch marks another milestone for Rocket Lab as we continue to enable innovative companies like Kinéis to push the boundaries of global IoT connectivity. With each mission, we are bringing the world closer together, allowing vital data to be transmitted from the remotest corners of the Earth."
Across 53 launches Rocket Lab has now deployed 197 satellites for a diverse range of customers and missions, including NASA missions to the Moon, the National Reconnaissance Office and Space Force missions supporting national security and defense, scientific research to combat climate change, and commercial constellations providing vital data and services to millions of people on Earth.

RKLB

Reported Friday, Rocket Lab Successfully Launches 53rd Mission, Deploys Satellites for French IoT Company Kinéis

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today presented data informing clinical strategies for switching patients to UZEDY&#xAE;, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly subcutaneous injection of Perseris&#xAE; (RBP-7000). The results were presented during the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress taking place between September 21-24, 2024, in Milan, Italy.
Schizophrenia is a complex medical condition that may require switching from an oral option or between different long-acting injectable options during the patient treatment journey. These data further clinical understanding of optimal treatment strategies when switching to UZEDY from Perseris&#xAE;.
"Schizophrenia patients and healthcare providers rely on evidence-based studies that can help inform their treatment decisions. That is why Teva is dedicated to building on our commitment to neuroscience and schizophrenia and helps provide these clinical insights on UZEDY switching strategies, along with its role in long-acting treatment options," said Eric Hughes, MD, PhD, Executive Vice President of Global R&amp;D and Chief Medical Officer at Teva. "Up to 80% of schizophrenia patients experience multiple relapses in the first five years, making switching treatments a common experience in the search for optimal treatment. With UZEDY, Teva is building a robust portfolio of research that can help determine if and when it may be the right long-acting option."
In a population pharmacokinetic (PopPK) analysis, simulations were conducted to predict pharmacokinetic (PK) exposures when switching to UZEDY 4-6 weeks after the last injection of once-monthly RBP-7000. The simulation models indicated that switching to UZEDY 4 weeks after the last dose of once-monthly RBP-7000 resulted in comparable PK properties of UZEDY at both the initial exposure and steady state. Comparable doses included UZEDY at 100 mg (once-monthly dosing) or 200 mg (once-every-two-months dosing) to 120 mg of once-monthly RBP-7000.1
Any switching strategy should be determined by clinicians on an individual patient basis, considering factors such as patient preference, scheduling convenience and potential tolerability issues or risk of symptom breakthrough.
"Every person living with schizophrenia has unique treatment needs and preferences that may also evolve over time. For my patients, I encourage discussion around key factors like treatment adherence, dosing frequency, symptom control, and rate of relapse which inform what treatment option may be the most appropriate," said Christoph Correll, MD, Professor of Psychiatry at the Zucker School of Medicine, Hempstead, NY. "For healthcare providers, there is also a significant knowledge gap in the available clinical data on switching patients between the various LAI treatment options, which have differing pharmacokinetic properties and dosing considerations. Insights from studies like these are crucial for researchers and clinicians like myself, as they help us become more informed and better serve our patients."
Additional key data being presented at ECNP 2024 included new quantitative results from the ADVANCE (Attitudes Driving Regional Differences in LAI Antipsychotic Utilization for Schizophrenia Among HCPs, Patients and Caregivers) surveys, including:
<ul>
<li>Among 447 people living with schizophrenia and 375 caregivers, most common patient-reported reasons for accepting an LAI (n=331) were improvement of symptoms/condition with LAIs (68%, n=224), recommendation by their HCP (65%, n=214) and ease of using LAIs versus oral antipsychotics (57%, n=189).1</li>
<li>Patients also reported using LAIs due to fewer side effects versus oral antipsychotics (38%, n=127) and to help prevent hospitalization (20%, n=67).1</li>
<li>Caregivers (n=229) reported that patients accepted LAIs based on ease of use versus oral antipsychotics (78%, n=178), to help prevent hospitalization (62%, n=143) and perception that LAIs would work better for improving condition/symptoms (62%, n=143).1</li>
<li>Among a sample of 791 HCPs from 8 different countries, most HCPs reported that the primary reason for recommending an LAI to a patient was nonadherence to oral medication, with the exception of South Korea where the most common reason was that an LAI would be more efficacious than oral.1</li>
<li>The primary reasons cited for not recommending an LAI were patient clinical characteristics and the lack of an available LAI formulation of the patient's current oral treatment, except for China and South Korea, where the primary reasons were LAI cost to patient and LAI product not marketed, respectively.</li>
</ul>

TEVA

Reported Saturday, Teva Unveils Data on UZEDY Injection Switching Strategy for Schizophrenia Treatment at ECNP

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. In the study, TEV-‘749 met the primary endpoint, demonstrating significant improvements in the Positive and Negative Syndrome Scale (PANSS)&nbsp;total score from baseline to week 8, as well as key secondary endpoints with improvements in both the Clinical Global Impression-Severity (CGI-S) scale and the Personal and Social Performance (PSP) scale score, compared to placebo at week 8. Additionally, SOLARIS (Period 1) and Phase 1 safety results demonstrated no incidence of post-injection delirium/sedation syndrome (PDSS) in participants taking TEV-‘749 to date.1 The overall safety profile was consistent with other oral acting olanzapine options. These data were presented during the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress taking place between September 21-24, 2024, in Milan, Italy.
Schizophrenia is a complex medical condition that may require switching from oral options or between different long-acting injectable (LAI) options during the patient treatment journey. These data demonstrate the potential role of TEV-‘749 as an LAI treatment option for schizophrenia patients taking daily oral olanzapine or other antipsychotic medications. Currently, the only long-acting olanzapine treatment option for schizophrenia carries a risk for PDSS, the sudden and unexpected onset of delirium or sedation when medication is released too quickly into the blood after receiving an intramuscular injection of long-acting olanzapine.1
"Teva is dedicated to building on its commitment to neuroscience by developing new long-acting injectable treatment options like TEV-‘749 that may help address unmet needs in schizophrenia for patients and healthcare providers," said Eric Hughes, MD, PhD, Executive Vice President of Global R&amp;D and Chief Medical Officer at Teva. "PDSS is a major barrier to the utilization of intramuscular olanzapine LAIs that exists today, and our SOLARIS findings fuel the continued development of TEV-‘749."
With nearly 30 years of clinical and real-world use, olanzapine is one of the most commonly prescribed 2nd generation oral antipsychotics for schizophrenia around the world. Its efficacy and safety profiles are well established.
"Developing a long-acting olanzapine formulation that poses potentially no risk of PDSS is crucial in preventing these dangerous episodes that otherwise limit the use of olanzapine to daily oral options," said Christoph Correll, MD, Professor of Psychiatry at the Zucker School of Medicine, Hempstead, NY. "With no PDSS observed in the SOLARIS trial to date, these data add to the growing body of evidence that TEV-‘749 may one day serve as an important treatment option for patients and healthcare providers who rely on olanzapine and also have needs or preferences that require a long-acting option."
Period 1 of the SOLARIS study is an 8-week, randomized, double-blind, placebo-controlled trial in patients aged 18-64 years diagnosed with schizophrenia, followed by an open-label safety period of up to 48 weeks (Period 2). Efficacy results from Period 1 of the SOLARIS study show that by week 8:
<ul>
<li>TEV-‘749 met its primary endpoint across all three dosing groups, with statistically significant mean differences in the change in PANSS total scores from baseline to week 8 of -9.71 points, -11.25 points, and -9.69 points versus placebo for the high (531 mg, corresponding to 20 mg/day of oral olanzapine), medium (425 mg, corresponding to 15 mg/day of oral olanzapine), and low (318 mg, corresponding to 10 mg/day of oral olanzapine) dose groups, respectively (all P&lt;0.0001).1</li>
<li>TEV-‘749 treatment significantly improved CGI-S scale scores across all three dosing groups, with reductions of -0.47 points (high), -0.61 points (medium), and -0.53 points (low) versus placebo from baseline to week 8 (all P&lt;0.0001).1</li>
<li>TEV-‘749 treatment significantly improved PSP scale scores across all three dosing groups, with increases of 4.93 points (high), 3.15 points (medium), and 4.63 points (low) versus placebo from baseline to week 8 (all P&lt;0.02).1 &nbsp;</li>
</ul>
The systemic safety profile of TEV-‘749 was consistent with other approved formulations of olanzapine, with no new safety signals identified. Additional safety and tolerability results from Period 1 (917 active injections) through week 8 of the SOLARIS study show that:
<ul>
<li>There were no reported cases of PDSS.1</li>
<li>Treatment-emergent adverse events that occurred more often in patients receiving TEV-‘749 versus placebo included weight increase (35% [173/500] versus 8% [13/167]), injection site induration (13% [64/500] versus 2% [4/167]), injection site pain (10% [50/500] versus 4% [7/167]) and injection site erythema (10% [48/500] versus 1% [1/167]).1</li>
<li>Serious adverse events and discontinuations due to adverse events were reported in 1% (7/500) and 3% (16/500) of patients treated with TEV-‘749, respectively, and in 2% (3/167) and 3% (5/167) of patients treated with placebo, respectively.1 &nbsp;</li>
</ul>
Also presented at ECNP 2024, results from the Phase 1 study of TEV-'749 show similar safety and tolerability results, including no reports of PDSS events. Additionally, a presented pre-clinical study suggests that the subcutaneous route of administration and formulation characteristics of TEV-'749 appear to greatly reduce the hypothesized risk of PDSS occurrence for patients receiving the treatment.
The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.
TEV-‘749 utilizes SteadyTeq&#x2122;, a copolymer technology proprietary to Medincell that provides a controlled steady release of olanzapine.
TEV-‘749 is an investigational once-monthly subcutaneous LAI of the 2nd generation antipsychotic olanzapine and is not approved by any regulatory authority for any use, and its safety and efficacy are not established.

Reported Saturday, Teva's New Schizophrenia Treatment TEV-749 Meets Key Endpoints in Phase 3 Study

IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on&nbsp;Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.
&nbsp;
The investor webcast presentation agenda to review the interim Phase 2 clinical data and regulatory update for darovasertib in neoadjuvant UM will be the following:
<ul>
<li>Market introduction: annual incidence of UM</li>
<li>Registrational trial design based on FDA Type C meeting guidance</li>
<li>Phase 2 clinical data update
<ul>
<li>Baseline characteristics</li>
<li>AE profile</li>
<li>Clinical efficacy from Phase 2 company-sponsored and&nbsp;IST</li>
</ul>
</li>
</ul>
The investor webcast and conference call will include participation from a key opinion leader. IDEAYA management, Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences, and Darrin Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences, will also serve as presenters. The link to the investor webcast will be available on the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260191-1&amp;h=3377453956&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DaZNKgmjyzMiSsMV9B-Z278MGSBmp7QT7selVCYln7cme2BlMujELVbZsAvmEnglHhEEP1UAiAlw0tD0KLcJ62HpJpBtsaRzd339TU33692AfxZb1oqzMHlryeai5G-mo&amp;a=Investor">Investor</a> Relations&nbsp;Events section of the Company's website at: <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260191-1&amp;h=1643450813&amp;u=https%3A%2F%2Fir.ideayabio.com%2Fevents&amp;a=https%3A%2F%2Fir.ideayabio.com%2Fevents">https://ir.ideayabio.com/events</a>. Registration is available at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260191-1&amp;h=1643450813&amp;u=https%3A%2F%2Fir.ideayabio.com%2Fevents&amp;a=https%3A%2F%2Fir.ideayabio.com%2Fevents">https://ir.ideayabio.com/events</a> or <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260191-1&amp;h=1935289296&amp;u=https%3A%2F%2Flifescievents.com%2Fevent%2Fideaya-3%2F&amp;a=https%3A%2F%2Flifescievents.com%2Fevent%2Fideaya-3%2F">https://lifescievents.com/event/ideaya-3/</a> in advance of the event.

IDYA

Reported Sunday, IDEAYA Biosciences to Announce Interim Phase 2 Data for Darovasertib in Uveal Melanoma

Pedro Azagra, CEO of Avangrid, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGR#NYSE">AGR</a>), a leading sustainable energy company and member of the Iberdrola Group, today issued the following statement at the start of Climate Week NYC. "Under the leadership of Iberdrola's Executive Chairman Ignacio Galán, Avangrid has embarked on a journey to purposefully and confidently lead the clean energy transition in the United States. We recognize that we stand at a pivotal moment in our history, as we mark the beginning of Climate Week NYC, where the urgency to fight climate change has never been greater. Every devastating storm, heat wave, or drought – likely made more extreme due to our changing climate – demonstrates the need for immediate action. In keeping with this year's theme, it's time to accelerate progress. With a growing portfolio of over 9 Gigawatts of clean energy installed, and with America's first large-scale offshore wind farm currently under construction, we aren't just promising a greener future, we are building it today. Along the way, we are making record investments in our networks to help our millions of power customers weather the next extreme event fueled by climate change. The demand for safe, clean, affordable electricity to power our homes and businesses will keep growing. Together with our global partners, Avangrid has been at the forefront of the energy transition and will continue forging ahead to achieve our common goal of creating a healthier tomorrow that will ensure the well-being of generations to come."

Reported Sunday, Avangrid CEO Pedro Azagra Urges Climate Action, Highlights Clean Energy Progress at Climate Week NYC

While the first day of fall was ushered in across the Gulf Coast region at 7:43&nbsp;a.m. central time Sunday, there are still several more weeks remaining in the 2024 hurricane season. That is why CenterPoint Energy has been closely monitoring weather forecasts in the Gulf of Mexico this weekend and following its standard preparedness protocols. Greater clarity on the weather situation is expected from the National Hurricane Center in the coming days, but CenterPoint and its frontline electric and gas crews remain ready.
<a href="https://mma.prnewswire.com/media/95201/centerpoint_energy_logo.html"><img src="https://mma.prnewswire.com/media/95201/centerpoint_energy_logo.jpg" alt="CenterPoint Energy logo. (PRNewsFoto)" /></a>
In preparation for potential severe weather across the Gulf Coast, CenterPoint will continue to monitor and prepare as the situation evolves. In the event it is needed, the company will begin the process of securing work sites, preparing crews and equipment, and securing additional frontline resources from mutual assistance companies, as necessary. And while autumn days may be on everyone's minds, the company wants to remind customers and the public to develop an emergency plan and assemble or restock a <a href="https://youtu.be/oshsLHzUEOg">storm preparedness kit</a> that includes essential items such as nonperishable food, water, flashlights, batteries, a first aid kit, any necessary medications, a battery-powered radio, and a portable charger for mobile devices.&nbsp;
"It's important to be mindful of the weather and plan ahead," said Darin Carroll, Senior Vice President, Electric Business. "Although schools are back in class and football games highlight our weekends, we have to keep an eye on the Gulf and be prepared to act quickly, if necessary. We want our customers and communities to know that we are constantly monitoring the weather and refining and updating our preparations and plans."
Carroll added, "Since Hurricane Beryl we've made significant improvements to our electric system as part of the Greater Houston Resiliency Initiative. We believe our actions since Beryl will help improve the resiliency and reliability of the electric grid and better meet our customers' expectations."
Greater Houston Resiliency Initiative
Across Greater Houston, CenterPoint is taking action now to improve resiliency and help reduce the risk of outages this hurricane season.&nbsp;
As part of the first phase of its Greater Houston Resiliency Initiative, throughout August CenterPoint crews and contractors installed more than 1,100 stronger and more resilient fiberglass poles, trimmed vegetation along more than 2,000 miles of power lines and installed more than 300 automation devices in neighborhoods all over Houston. The company's next step is taking the boldest series of resiliency actions in its nearly 160-year history, including additional system hardening, strategic undergrounding, self-healing grid technology, and further enhancements to its outage tracker.
Call to Action: Power Alert Service
Customers should remember that a storm is a powerful force of nature that can cause significant damage and widespread lengthy electricity outages. Conditions can also change unexpectedly and for the worse.
Customers are encouraged to enroll in <a href="https://www.centerpointenergy.com/en-us/residential/services/electric-utility/outage-center/power-alert-service?sa=ho&amp;WT.mc_id=VanURL_PAS_On">Power Alert Service&#xAE;</a> to receive outage details, estimated restoration times as available or determined, and customer-specific restoration updates in the event of severe weather. With the option to receive updates via phone call, text or email, Power Alert Service&#xAE; helps keep customers informed of restoration progress during an outage event. Customers can also find additional resources at <a href="https://www.centerpointenergy.com/en-us/residential/safety/weather-storm-center?sa=ho">CenterPointEnergy.com/StormCenter</a>.&nbsp;
New and Improved Outage Tracker with Greater Web Resiliency
CenterPoint's new and improved <a href="http://centerpointenergy.com/OutageTracker#sthash.5KkUvaRI.dpuf">Outage Tracker</a> can be used to update individual customers on their expected restoration date as soon as possible after restoration expectations are determined.&nbsp;
To learn more about Outage Tracker's new features and functionality, watch the demonstration&nbsp;<a href="https://www.youtube.com/watch?v=UY40X8UFq5E">video</a>.
For an in-depth, step-by-step guide to using the Outage Tracker,&nbsp;<a href="https://www.centerpointenergy.com/en-us/Documents/Outage_Tracker_Walkthrough.pdf">click here</a>.&nbsp;&nbsp;
Customers with Critical Needs
Because CenterPoint Energy cannot guarantee an uninterrupted, regular or continuous power supply during a severe weather event, customers who depend on electricity for life-sustaining equipment are encouraged to make alternate arrangements for on-site backup capabilities or other alternatives in the event of loss of electric service.&nbsp;
During pre-storm preparations and post-storm recovery efforts, CenterPoint urges customers to stay informed of weather conditions and warnings or advisories issued by local authorities by paying close attention to announcements from local news outlets for important information regarding ongoing conditions and recovery efforts. The company also recommends that customers follow these important natural gas and electric safety tips:&nbsp;

Reported Sunday, CenterPoint Energy Prepares for Hurricane Season, Urges Customers to Stay Ready

Faraday Future Announced It Delivered An FF 91 2.0 Futurist Alliance To Born Leaders Entertainment In The Famous Warwick Club In Hollywood On September 20

IPHA

Innate Pharma Announced That The US FDA Has Cleared Its Investigational New Drug (IND) Application To Initiate A Phase 1 Clinical Study Of IPH4502, A Nectin-4 ADC To Be Developed In Solid Tumors

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript

Michael Ryskin, an analyst from Bank of America Securities, reiterated the Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report). Th...

Buy Rating Affirmed for Maravai Lifesciences Amid Strong Growth Prospects and Operational Investments

Robert W. Baird analyst Catherine Ramsey Schulte has maintained their bullish stance on MRVI stock, giving a Buy rating yesterday. Catherine Ramsey...

Maravai Lifesciences: A Strong Buy on Robust Revenue Growth and Strategic Expansion

In a report released today, Justin Bowers from Deutsche Bank maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report), wit...

Deutsche Bank  Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)

Maravai cut at Morgan Stanley; Pfizer/BioNTech headwinds cited

RBC Capital analyst Conor McNamara reiterated a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) today and set a price target o...

Maravai Lifesciences Holdings (MRVI) Gets a Buy from RBC Capital

Maravai LifeSciences jumps on report of Repligen takeover offer

Maravai LifeSciences may be worth $15 to $20 share in a takeout - analyst

PGIM Jennison Health Sciences Fund Q2 2024 Commentary

In a report released on September 6, Brandon Couillard from Wells Fargo maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research R...

Maravai Lifesciences Holdings (MRVI) Gets a Buy from Wells Fargo

ABBV

AMGN

APLS

ARGX

BNTX

CABA

ISRG

MRNS

PAAA

PFRL

PHYL

PJFG

PJIO

PMIO

PSDM

PTRB

PULS

VRTX

Press Releases

Maravai LifeSciences Reports First Quarter 2024 Financial Results

Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule

TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024

Management

Maravai LifeSciences Appoints Trey Martin to Board of Directors

Maravai LifeSciences Reports Second Quarter 2024 Financial Results

Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule

Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Maravai LifeSciences

Maravai LifeSciences (MRVI) Forecast

Maravai LifeSciences (NASDAQ:MRVI) Stock, Quote.Headers.trade-ideas